Ramatroban

Ramatroban (INN) (also known as Bay-u3405)[1] is a thromboxane receptor antagonist.[2]

Ramatroban
Clinical data
Trade namesBaynas
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral (tablets)
ATC code
  • None
Legal status
Legal status
  • Rx-only (JP)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.159.668
Chemical and physical data
FormulaC21H21FN2O4S
Molar mass416.47 g·mol−1
3D model (JSmol)

It is also a DP2 receptor antagonist.[3]

It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the trade name Baynas.

References

  1. "Ramatroban (compound)". PubChem. National Center for Biotechnology Information. Retrieved 22 June 2019.
  2. Sugimoto H, Shichijo M, Iino T, et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. doi:10.1124/jpet.102.046748. PMID 12649388.
  3. Royer JF, Schratl P, Carrillo JJ, et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.
  4. Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease" (PDF). Stroke. 21 (12 Suppl): IV149–51. PMID 2260140.
  5. Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.